ULTRAGENYX PHARMACEUTICAL INC. Financials Ultragenyx Pharmaceutical Inc.
Equities
RARE
US90400D1081
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 44.24 USD | +0.89% |
|
+4.41% | -7.49% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 2,467 | 9,158 | 5,732 | 3,248 | 3,926 | 3,678 | - | - |
| Enterprise Value (EV) 1 | 1,712 | 7,956 | 4,992 | 2,500 | 3,149 | 3,343 | 3,379 | 3,678 |
| P/E ratio | -6 x | -45.1 x | -12.6 x | -4.58 x | -5.8 x | -6.84 x | -8.46 x | -13.3 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 23.8 x | 33.8 x | 16.3 x | 8.94 x | 9.04 x | 7.15 x | 5.84 x | 4.22 x |
| EV / Revenue | 16.5 x | 29.4 x | 14.2 x | 6.88 x | 7.25 x | 6.5 x | 5.37 x | 4.22 x |
| EV / EBITDA | -4.12 x | -25 x | -13.5 x | -3.96 x | -5.8 x | -6.63 x | -8.57 x | -28.7 x |
| EV / FCF | -4.62 x | -45.2 x | -12.1 x | -5.03 x | -6.07 x | -8.12 x | -8.81 x | -10.7 x |
| FCF Yield | -21.6% | -2.21% | -8.25% | -19.9% | -16.5% | -12.3% | -11.4% | -9.33% |
| Price to Book | 3.78 x | 7.3 x | 6.32 x | 9.23 x | 12.8 x | 4.95 x | 4.42 x | 4.58 x |
| Nbr of stocks (in thousands) | 57,771 | 66,156 | 68,162 | 70,106 | 82,106 | 83,133 | - | - |
| Reference price 2 | 42.71 | 138.4 | 84.09 | 46.33 | 47.82 | 44.24 | 44.24 | 44.24 |
| Announcement Date | 2/13/20 | 2/11/21 | 2/10/22 | 2/16/23 | 2/15/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 103.7 | 271 | 351.4 | 363.3 | 434.2 | 514.7 | 629.8 | 871.8 |
| EBITDA 1 | -415.6 | -317.9 | -368.5 | -630.7 | -543.2 | -504.2 | -394.4 | -128.3 |
| EBIT 1 | -424.2 | -330.1 | -381.7 | -648.9 | -569.2 | -496.6 | -434.1 | -268.3 |
| Operating Margin | -408.98% | -121.8% | -108.63% | -178.6% | -131.08% | -96.48% | -68.93% | -30.77% |
| Earnings before Tax (EBT) 1 | -399.4 | -185.4 | -453 | -701.7 | -608.5 | -534.3 | -464.2 | -300.6 |
| Net income 1 | -402.7 | -186.6 | -454 | -707.4 | -606.6 | -531.9 | -459.5 | -314.8 |
| Net margin | -388.31% | -68.84% | -129.2% | -194.71% | -139.7% | -103.34% | -72.97% | -36.11% |
| EPS 2 | -7.120 | -3.070 | -6.700 | -10.12 | -8.250 | -6.466 | -5.230 | -3.323 |
| Free Cash Flow 1 | -370.2 | -176.1 | -411.8 | -496.6 | -519.1 | -411.7 | -383.7 | -343 |
| FCF margin | -356.96% | -64.98% | -117.18% | -136.68% | -119.53% | -79.99% | -60.92% | -39.35% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 2/13/20 | 2/11/21 | 2/10/22 | 2/16/23 | 2/15/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 81.65 | 83.39 | 79.94 | 89.34 | 90.7 | 103.3 | 100.5 | 108.3 | 98.05 | 127.4 | 116.8 | 125.9 | 129.8 | 142.9 | 129.4 |
| EBITDA | -86.61 | -99.03 | - | -137.1 | -220.4 | -140.7 | -148.9 | -142.6 | -137.9 | -113.8 | - | - | - | - | - |
| EBIT 1 | -89.83 | -102.6 | -136.6 | -141.6 | -225.1 | -145.6 | -154.1 | -148 | -145.1 | -122 | -133.3 | -125.2 | -123.2 | -118.7 | -125.7 |
| Operating Margin | -110.02% | -122.99% | -170.93% | -158.48% | -248.14% | -140.91% | -153.34% | -136.61% | -147.98% | -95.81% | -114.11% | -99.48% | -94.94% | -83.02% | -97.18% |
| Earnings before Tax (EBT) 1 | -72.82 | -122.4 | -151.8 | -157.9 | -238.8 | -153.3 | -163.5 | -159.1 | -159 | -126.9 | -138.3 | -131.2 | -127.8 | -119.7 | -132.4 |
| Net income 1 | -73 | -122.5 | -152.3 | -158.2 | -245.1 | -151.8 | -164 | -159.8 | -159.6 | -123.2 | -139.7 | -131.4 | -128.6 | -124 | -132.1 |
| Net margin | -89.41% | -146.85% | -190.55% | -177.03% | -270.23% | -146.91% | -163.16% | -147.57% | -162.82% | -96.7% | -119.58% | -104.37% | -99.05% | -86.76% | -102.11% |
| EPS 2 | -1.080 | -1.790 | -2.190 | -2.260 | -3.500 | -2.160 | -2.330 | -2.250 | -2.230 | -1.520 | -1.752 | -1.642 | -1.586 | -1.519 | -1.540 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/2/21 | 2/10/22 | 5/5/22 | 7/28/22 | 11/2/22 | 2/16/23 | 5/4/23 | 8/3/23 | 11/2/23 | 2/15/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 755 | 1,202 | 740 | 748 | 777 | 334 | 298 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -370 | -176 | -412 | -497 | -519 | -412 | -384 | -343 |
| ROE (net income / shareholders' equity) | -63.8% | -20.6% | -43.7% | -111% | -193% | -110% | -66.7% | -39.8% |
| ROA (Net income/ Total Assets) | -43.4% | -12.9% | -27.7% | -46.1% | -40% | -39.2% | -35.4% | -31.2% |
| Assets 1 | 927.5 | 1,447 | 1,641 | 1,534 | 1,518 | 1,357 | 1,300 | 1,007 |
| Book Value Per Share 2 | 11.30 | 19.00 | 13.30 | 5.020 | 3.740 | 8.940 | 10.00 | 9.660 |
| Cash Flow per Share 2 | -6.100 | -2.170 | -4.940 | -5.440 | -6.460 | -5.460 | -4.140 | - |
| Capex 1 | 24.8 | 43.9 | 73.1 | 116 | 44.3 | 46.7 | 44.3 | 43.8 |
| Capex / Sales | 23.94% | 16.2% | 20.8% | 31.96% | 10.19% | 9.07% | 7.04% | 5.02% |
| Announcement Date | 2/13/20 | 2/11/21 | 2/10/22 | 2/16/23 | 2/15/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
44.24
USD
Average target price
89.52
USD
Spread / Average Target
+102.36%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -7.49% | 3.64B | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- RARE Stock
- Financials Ultragenyx Pharmaceutical Inc.
